Research for Resistance Factors in the Treatment of Lymphoid Hemopathy

Starting soon

Conditions studied: MATURE B-CELL LYMPHOIDS

In brief

In order to promote translational research on the molecular pathways involved in resistance to treatments for mantle cell lymphoma (MCL), the clinical haematology department of the University Hospital Center (CHU) of Nantes has established, since 2016, the REFRACT-LyMa (Research on Factors of Resistance to Chemotherapies and Innovative Therapies in Mantle Cell Lymphoma) cohort-biocollection of blood and bone marrow samples from patients with MCL. Thanks to the close collaborations with team 11 of the Integrated Cancer Research and Immunology Center Nantes Angers (CRCI²NA), which specializes in studying the molecular pathways involved in resistance to treatments for hematological cancers, we wish to broaden the scope of research to other B-cell non-Hodgkin lymphomas (B-NHL). That is why today the REFRACT-LyMa cohort-biocollection aims to expand to malignant hematopathies involving mature B cells (Research on Factors of Resistance to Chemotherapies and Innovative Therapies in Mature B-Cell Lymphoid Hemopathies).

Key facts

Study ID: NCT07385612
Run by: Nantes University Hospital
People needed: 80
Starts: 2026-06-01
Expected to finish: 2036-06-01
Last updated by the study team: 2026-06-12

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Patient affected by B-NHL (at diagnosis or relapse).
Patient who has signed the consent form.
Patient affiliated with a social security system.

You may not qualify if…

Minor patients.
Adults under guardianship.
Protected persons.

Where it is running

CHD Vendée — La Roche-sur-Yon, France
CHU Nantes — Nantes, France
CHU de Poitiers — Poitiers, France
CH de Saint-Nazaire — Saint-Nazaire, France

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.